Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Arbutus Biopharma Cp (ABUS)

2.71   0.02 (0.74%) 01-25 23:23
Open: 2.62 Pre. Close: 2.69
High: 2.79 Low: 2.61
Volume: 2,330,227 Market Cap: 367M
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical trial collaboration agreement with Vaccitech plc to evaluate a therapeutic combination for the treatment of subjects with chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.795 - 2.808 2.808 - 2.82
Low: 2.578 - 2.593 2.593 - 2.607
Close: 2.685 - 2.71 2.71 - 2.733

Technical analysis

as of: 2022-01-25 4:21:53 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 4.32     One year: 5.26
Support: Support1: 2.41    Support2: 2.01
Resistance: Resistance1: 3.70    Resistance2: 4.50
Pivot: 3.20
Moving Average: MA(5): 2.78     MA(20): 3.37
MA(100): 3.83     MA(250): 3.49
MACD: MACD(12,26): -0.30     Signal(9): -0.22
Stochastic oscillator: %K(14,3): 13.52     %D(3): 7.74
RSI: RSI(14): 27.64
52-week: High: 6.50  Low: 2.41  Change(%): -28.3
Average Vol(K): 3-Month: 10295  10-Days: 3295

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
ABUS has closed above bottom band by 14.0%. Bollinger Bands are 34.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 13 Aug 2021
Seeking Alpha Catalyst Watch - Seeking Alpha

Fri, 22 Jun 2018
ABUS News Today (Arbutus Biopharma) - MarketBeat

Wed, 31 Dec 1969


Wed, 31 Dec 1969


Wed, 31 Dec 1969


Wed, 31 Dec 1969


Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 135
Shares Float (M) 93
% Held by Insiders 30.77
% Held by Institutions 26.67
Shares Short (K) 4,550
Shares Short P. Month (K) 2,280

Stock Financials

EPS -0.917
EPS Est This Year -1.390
EPS Est Next Year -1.350
Book Value (p.s.) -0.280
Profit Margin
Operating Margin -661.12
Return on Assets (ttm) -28.3
Return on Equity (ttm) -63.3
Qtrly Rev. Growth 119.3
Gross Profit (p.s.) -0.300
Sales Per Share 0.075
EBITDA (p.s.) -0.484
Qtrly Earnings Growth
Operating Cash Flow (M) -63
Levered Free Cash Flow (M) -36

Stock Valuations

PE Ratio -2.96
PEG Ratio
Price to Book value -9.68
Price to Sales 36.04
Price to Cash Flow

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.